EGFR and non-small cell lung carcinoma: Currently, two main categories of targeted therapy drugs are used for advanced, metastatic, or recurrent NSCLC: monoclonal antibodies (e.g., cetuximab and panitumumab) and small molecule kinase inhibitors (e.g., gefitinib and erlotinib), which bind to the extracellular region of EGFR [10, 11].